文献速递治疗药物监测与药物基因组学特殊人群用药

大型农村卫生系统实施CYP2C19和CYP2D6基因分型指导抗抑郁药使用

Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system.
PubMed 文献 · Am J Health Syst Pharm · 2024-01-01

本文描述了在大型农村非营利卫生系统Sanford Health中实施并持续维护以CYP2C19和CYP2D6为重点的药物基因组学检测,用以指导抗抑郁和抗焦虑药物处方。该系统自2014年起开展检测,通过临床药师审核结果、电子病历决策支持及跨学科门诊等多管齐下的方式持续更新。结论认为该项目的实施与维护需要人与信息学资源相结合的多方面策略。

要点

  • Sanford Health自2014年起实施CYP2C19和CYP2D6基因分型检测指导抗抑郁和抗焦虑药物处方。
  • 药物基因组学临床药师审核结果并在电子病历中提供指导文档,决策支持系统提供警示和基因组指示。
  • 与健康计划合作扩大了焦虑或抑郁患者接受药物基因组学检测的可及性。

核心结论

  • Sanford Health指导抗抑郁和抗焦虑药物使用的药物基因组学项目的实施与维护持续演进,需要依赖人与信息学资源的多管齐下方法。

研究设计与样本

  • 描述性实施经验总结,介绍大型农村非营利卫生系统Sanford Health自2014年起实施的CYP2C19和CYP2D6药物基因组学检测项目。

主要发现

  • 项目通过教育材料、临床药师审核结果并记录指导文档、电子病历决策支持(包括中断性警示、非中断性警示和基因组指示)以及转诊式跨学科门诊等多途径支持处方。
  • 与健康计划合作扩大了焦虑或抑郁患者接受药物基因组学检测的可及性。
  • 随着指南、基因型到表型转换、检测面板及其他资源更新,项目实施方法也随之调整。

临床怎么用

  • 在卫生系统中实施CYP2C19和CYP2D6基因分型检测以指导抗抑郁和抗焦虑药物处方时,可结合临床药师审核、电子病历决策支持和患者教育等多方面资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We describe the implementation and ongoing maintenance of CYP2C19 and CYP2D6 focused pharmacogenetic (PGx) testing to guide antidepressant and antianxiety medication prescriptions in a large rural, nonprofit health system. SUMMARY: Depression and anxiety are common psychiatric conditions. Sanford Health implemented PGx testing for metabolism of cytochrome P450 (CYP) isozymes 2C19 and 2D6 in 2014 to inform prescribing for multiple medications, including antidepressant and antianxiety therapies. As guidelines, genotype to phenotype translation, panel offerings, and other resources are updated, we adapt our approach. We make educational and informational materials available to providers and patients. Pharmacogenomic clinical pharmacists review PGx results with discrete values and provide guidance documentation in the electronic medical record. A robust clinical decision support system is in place to provide interruptive alerts, noninterruptive alerts, and genomic indicators. A referral-based interdisciplinary clinic is also available to provide in-depth education to patients regarding PGx results and implications. Additionally, partnering with our health plan has expanded access to PGx testing for patients with anxiety or depression. CONCLUSION: The implementation and maintenance of Sanford Health's PGx program to guide antidepressant and antianxiety medication use continues to evolve and requires a multipronged approach relying on both human and informatics-based resources.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Petry NJ, Van Heukelom J, Schultz AJ, et al. Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system. Am J Health Syst Pharm. 2024. PMID: 38546726. doi:10.1093/ajhp/zxae083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。